A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes

G Viberti; S E Kahn; D A Greene; W H Herman; B Zinman; R R Holman; S M Haffner; D Levy; J M Lachin; R A Berry; M A Heise; N P Jones; M I Freed

doi:10.2337/diacare.25.10.1737

A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes

G Viberti, S E Kahn, D A Greene, W H Herman, B Zinman, R R Holman, S M Haffner, D Levy, J M Lachin, R A Berry, M A Heise, N P Jones, M I Freed

King's College London

Research output: Contribution to journal › Article › peer-review

245 Citations (Scopus)

Abstract

OBJECTIVE: Therapies with metformin, sulfonylureas, or insulin improve glycemic control in the short term but do not prevent progressive islet beta-cell failure or long-term deterioration in glycemia. Our goal was to evaluate, in patients recently diagnosed with type 2 diabetes (

Original language	English
Pages (from-to)	1737 - 1743
Number of pages	7
Journal	Diabetes Care
Volume	25
Issue number	10
DOIs	https://doi.org/10.2337/diacare.25.10.1737
Publication status	Published - Oct 2002

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2337/diacare.25.10.1737

Cite this

Viberti, G., Kahn, S. E., Greene, D. A., Herman, W. H., Zinman, B., Holman, R. R., Haffner, S. M., Levy, D., Lachin, J. M., Berry, R. A., Heise, M. A., Jones, N. P., & Freed, M. I. (2002). A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care, 25(10), 1737 - 1743. https://doi.org/10.2337/diacare.25.10.1737

@article{5f7bff90d05b4ae58d520514ddaf3718,

title = "A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes",

abstract = "OBJECTIVE: Therapies with metformin, sulfonylureas, or insulin improve glycemic control in the short term but do not prevent progressive islet beta-cell failure or long-term deterioration in glycemia. Our goal was to evaluate, in patients recently diagnosed with type 2 diabetes (",

author = "G Viberti and Kahn, {S E} and Greene, {D A} and Herman, {W H} and B Zinman and Holman, {R R} and Haffner, {S M} and D Levy and Lachin, {J M} and Berry, {R A} and Heise, {M A} and Jones, {N P} and Freed, {M I}",

year = "2002",

month = oct,

doi = "10.2337/diacare.25.10.1737",

language = "English",

volume = "25",

pages = "1737 -- 1743",

journal = "Diabetes Care",

publisher = "American Diabetes Association",

number = "10",

}

Viberti, G, Kahn, SE, Greene, DA, Herman, WH, Zinman, B, Holman, RR, Haffner, SM, Levy, D, Lachin, JM, Berry, RA, Heise, MA, Jones, NP & Freed, MI 2002, 'A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes', Diabetes Care, vol. 25, no. 10, pp. 1737 - 1743. https://doi.org/10.2337/diacare.25.10.1737

TY - JOUR

T1 - A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes

AU - Viberti, G

AU - Kahn, S E

AU - Greene, D A

AU - Herman, W H

AU - Zinman, B

AU - Holman, R R

AU - Haffner, S M

AU - Levy, D

AU - Lachin, J M

AU - Berry, R A

AU - Heise, M A

AU - Jones, N P

AU - Freed, M I

PY - 2002/10

Y1 - 2002/10

N2 - OBJECTIVE: Therapies with metformin, sulfonylureas, or insulin improve glycemic control in the short term but do not prevent progressive islet beta-cell failure or long-term deterioration in glycemia. Our goal was to evaluate, in patients recently diagnosed with type 2 diabetes (

AB - OBJECTIVE: Therapies with metformin, sulfonylureas, or insulin improve glycemic control in the short term but do not prevent progressive islet beta-cell failure or long-term deterioration in glycemia. Our goal was to evaluate, in patients recently diagnosed with type 2 diabetes (

UR - http://www.scopus.com/inward/record.url?scp=0036781182&partnerID=8YFLogxK

U2 - 10.2337/diacare.25.10.1737

DO - 10.2337/diacare.25.10.1737

M3 - Article

VL - 25

SP - 1737

EP - 1743

JO - Diabetes Care

JF - Diabetes Care

IS - 10

ER -

A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this